Shire's acquisition of Viropharma last year helped its sales and earnings rocket in 2014, although chief executive Flemming Ornskov said growth in 2015 will be slower. Full-year sales grew 23 per ...
Shire is to acquire rare disease company ViroPharma for $4.2 billion in a strategic move to boost its orphan drug portfolio. ViroPharma is a high growth, rare disease biopharma company ...
Even with a "brutal" push to hit neutral cash, as one supplier described it, Vistry will also end the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback